University of Colorado Cancer Center
V

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L Setting

By University of Colorado Cancer Center FEATURING Virginia Borges
April 13, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi

Featured Video

22:25
Novartis Oncology

The Importance of Dosing and Patient Adherence in HR+/HER2- mBC

Feat. N. McAndrew

Related Content

AUTOPLAY
11:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
17:39
Yale School of Medicine

2023 Menopause Update

Feat. M. Minkin
13:03
Novartis Oncology

CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…

Feat. D. Slamon
24:36
ESMO 2022 Conference Coverage

ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates

Feat. H. Rugo, J. O'Shaughnessy
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
53:42
PleXus Communications

Managing Woman's Health in Menopause: Evolving Approaches for t…

Feat. J. Simon, T. Iyer, A. Fiffick, M. Minkin
03:05
ecancer

ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET…

Feat. D. Slamon
08:38
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Utility of Ki67 in Guiding Adjuvant Abema…

Feat. R. Patel
18:49
Yale School of Medicine

Menopause and Hot Flashes: What Medications are Available?

Feat. M. Minkin
22:29
ESMO 2022 Conference Coverage

ESMO 2022 on Adjuvant Endocrine Therapy for BC: Who Needs More Than …

Feat. E. de Azambuja
29:44
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Optimal Duration of Endocrine Therapy for Breast Cancer

Feat. V. Kaklamani
06:57
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ESR1 Mutational Landscape and Impact of C…

Feat. A. Medford
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar
03:32
UCSF School of Medicine

Management of Abemaciclib-Related Diarrhea in HR+/HER2- eBC

Feat. S. Donahue
09:32
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysi…

Feat. S. Tolaney
10:19
ASCO 2022 Conference Coverage

ASCO 2022 on Estradiol Levels in Premenopausal Women With HR+ BC on …

Feat. M. Tesch
07:49
ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 KEYNOTE-355 Trial: Outcomes in TNBC Patients…

Feat. H. Rugo